Managing Covid-19 in patients with heart failure: current status and future prospects

Hawani Sasmaya Prameswari,Iwan Cahyo Santosa Putra,Wilson Matthew Raffaello,Michael Nathaniel,Adrian Sebastian Suhendro,Achmad Fitrah Khalid,Raymond Pranata

DOI: https://doi.org/10.1080/14779072.2022.2132230

2022-10-14

Expert Review of Cardiovascular Therapy

Abstract:COVID-19 may contribute to decompensation of previously stable chronic HF or cause a de-novo heart failure, which may come from the hyperinflammatory response and subsequent increase in metabolic demand. Two independent investigators searched MEDLINE (via PubMed), Europe PMC, and ScienceDirect databases with the following search terms: COVID-19, heart failure, COVID-19 drugs, heart failure drugs, and device therapy. All of the included full-text articles were rigorously evaluated by both authors in case there was disagreement about whether research should be included or not. In total, 157 studies were included and underwent extensive reading by the authors. The World Health Organization (WHO) and the National Institute of Health (NIH) have published COVID-19 drug recommendations, although recommendations for HF-specific drug choices in COVID-19 are still lacking. We hope that this review can answer the void of comprehensive research data regarding the management options of HF in the COVID-19 condition so that clinicians can at least choose a more beneficial therapy or avoid combination therapies that have a high burden of side effects on HF; thus, morbidity and mortality in COVID-19 patients with HF may be reduced.